Matches in SemOpenAlex for { <https://semopenalex.org/work/W2290742707> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2290742707 startingPage "1926" @default.
- W2290742707 abstract "Background: RTCT can be curative in stage III NSCLC; however, most tumours progress despite intensive treatment. Efforts to understand and predict PR after RTCT are ongoing. The CTRT 99/97 Bronchial Carcinoma Therapy (BROCAT) study (Huber et al., JCO 2006) showed that, after induction CT with paclitaxel and carboplatin, RTCT with paclitaxel leads to longer PFS than RT alone. Here we present site of first PR data for patients in the BROCAT trial. Methods: We analysed site of first PR in the BROCAT study, comparing local, central nervous system (CNS), and systemic PR. Results: The BROCAT trial enrolled 303 patients, and, after induction CT, randomized 214 to RT (n=113) or RTCT (n=101). There was longer progression free survival in the RTCT arm, and a trend to longer overall survival. Site of first PR was available for 102 of 165 patients with progression and differed significantly between the treatment arms (p There was no significant association between histology and PR site (p = 0.328), but there was a trend to more CNS-PR in patients with large cell tumours compared to other histologies. Age and body mass index did not correlate with site of PR. Conclusion: RTCT seems to reduce the rate of systemic PR compared to RT after induction CT in Stage III NSCLC. It is not yet possible to predict which patients will benefit from which type and amount of additional CT." @default.
- W2290742707 created "2016-06-24" @default.
- W2290742707 creator A5003670561 @default.
- W2290742707 creator A5015476149 @default.
- W2290742707 creator A5046756579 @default.
- W2290742707 creator A5054440679 @default.
- W2290742707 creator A5057720144 @default.
- W2290742707 creator A5088481420 @default.
- W2290742707 creator A5088560327 @default.
- W2290742707 date "2014-09-01" @default.
- W2290742707 modified "2023-09-28" @default.
- W2290742707 title "Site of first progression (PR) differs between stage III NSCLC patients treated with simultaneous radiochemotherapy (RTCT) and those treated with radiotherapy (RT) alone following induction chemotherapy (CT)" @default.
- W2290742707 hasPublicationYear "2014" @default.
- W2290742707 type Work @default.
- W2290742707 sameAs 2290742707 @default.
- W2290742707 citedByCount "0" @default.
- W2290742707 crossrefType "journal-article" @default.
- W2290742707 hasAuthorship W2290742707A5003670561 @default.
- W2290742707 hasAuthorship W2290742707A5015476149 @default.
- W2290742707 hasAuthorship W2290742707A5046756579 @default.
- W2290742707 hasAuthorship W2290742707A5054440679 @default.
- W2290742707 hasAuthorship W2290742707A5057720144 @default.
- W2290742707 hasAuthorship W2290742707A5088481420 @default.
- W2290742707 hasAuthorship W2290742707A5088560327 @default.
- W2290742707 hasConcept C126322002 @default.
- W2290742707 hasConcept C141071460 @default.
- W2290742707 hasConcept C143998085 @default.
- W2290742707 hasConcept C146357865 @default.
- W2290742707 hasConcept C151730666 @default.
- W2290742707 hasConcept C168563851 @default.
- W2290742707 hasConcept C2776611710 @default.
- W2290742707 hasConcept C2776694085 @default.
- W2290742707 hasConcept C2777292972 @default.
- W2290742707 hasConcept C2777546739 @default.
- W2290742707 hasConcept C2778239845 @default.
- W2290742707 hasConcept C2780739268 @default.
- W2290742707 hasConcept C2781451048 @default.
- W2290742707 hasConcept C3019894029 @default.
- W2290742707 hasConcept C509974204 @default.
- W2290742707 hasConcept C71924100 @default.
- W2290742707 hasConcept C86803240 @default.
- W2290742707 hasConcept C90924648 @default.
- W2290742707 hasConceptScore W2290742707C126322002 @default.
- W2290742707 hasConceptScore W2290742707C141071460 @default.
- W2290742707 hasConceptScore W2290742707C143998085 @default.
- W2290742707 hasConceptScore W2290742707C146357865 @default.
- W2290742707 hasConceptScore W2290742707C151730666 @default.
- W2290742707 hasConceptScore W2290742707C168563851 @default.
- W2290742707 hasConceptScore W2290742707C2776611710 @default.
- W2290742707 hasConceptScore W2290742707C2776694085 @default.
- W2290742707 hasConceptScore W2290742707C2777292972 @default.
- W2290742707 hasConceptScore W2290742707C2777546739 @default.
- W2290742707 hasConceptScore W2290742707C2778239845 @default.
- W2290742707 hasConceptScore W2290742707C2780739268 @default.
- W2290742707 hasConceptScore W2290742707C2781451048 @default.
- W2290742707 hasConceptScore W2290742707C3019894029 @default.
- W2290742707 hasConceptScore W2290742707C509974204 @default.
- W2290742707 hasConceptScore W2290742707C71924100 @default.
- W2290742707 hasConceptScore W2290742707C86803240 @default.
- W2290742707 hasConceptScore W2290742707C90924648 @default.
- W2290742707 hasLocation W22907427071 @default.
- W2290742707 hasOpenAccess W2290742707 @default.
- W2290742707 hasPrimaryLocation W22907427071 @default.
- W2290742707 hasVolume "44" @default.
- W2290742707 isParatext "false" @default.
- W2290742707 isRetracted "false" @default.
- W2290742707 magId "2290742707" @default.
- W2290742707 workType "article" @default.